CNST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Dec 1970 @ 19:00):

Stats
Today's Volume	1.27M
Average Volume	1.57M
Market Cap	0.00
EPS	$0 ( 2021-08-03 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.734 (2.16%)

Insider Trading

Date	Person	Action	Amount	type
2021-07-15	Hoerter Steven L.	Sell	26 342	Stock Option (right to buy)
2021-07-15	Reeve Emma	Sell	60 000	Stock Option (Right to Buy)
2021-07-15	Reeve Emma	Sell	37 527	Stock Option (right to buy)
2021-07-15	Reeve Emma	Sell	73 428	Stock Option (right to buy)
2021-07-15	Reeve Emma	Sell	11 777	Stock Option (right to buy)

INSIDER POWER
0.00
Last 99 transactions
Buy: 291 157 \| Sell: 1 004 317

Volume Correlation

Long: 0.27 (neutral)

Short: 0.71 (moderate)

Signal:(80.978) Neutral

Constellation Correlation

10 Most Positive Correlations
TLMD	0.947
MDWT	0.94
RMRM	0.926
ATOM	0.923
SVOK	0.923
MDXG	0.92
NNOX	0.918
WWD	0.918
LIXT	0.916
MEIP	0.915

10 Most Negative Correlations
BOCH	-0.944
SMSI	-0.929
APTX	-0.92
TWKS	-0.917
UPLD	-0.913
MMAC	-0.905
NETE	-0.903
TTEC	-0.903
EYE	-0.901
INGN	-0.896

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Constellation Correlation - Currency/Commodity

0.30
( neutral )

0.37
( neutral )

-0.09
( neutral )

0.07
( neutral )

-0.08
( neutral )

0.10
( neutral )

Constellation Financials

Annual	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-4.49

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-4.49

FY	2019
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-3.04

FY	2018
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-5.00

Financial Reports:

No articles found.

Constellation

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.